William Blair equity research analyst Louie DiPalma was a guest on Bloomberg Tech for a story on SpaceX’s post-IPO quiet period, its competitive landscape, and the future of the company.

Equity Research
William Blair equity research analyst Louie DiPalma was a guest on Bloomberg Tech for a story on SpaceX’s post-IPO quiet period, its competitive landscape, and the future of the company.
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of Neuronetics, Inc. (STIM $1.39), a medical technology company that designs, manufactures, and markets noninvasive neuromodulation treatments for psychiatric disorders and operates interventional psychiatry centers.
With no small supply of ink having already been spilt on the midterms, in this Economics Weekly, Richard de Chazal focuses on the news from the QRA, which is increasingly becoming the Treasury’s equivalent of an FOMC meeting—an event where subtle changes in language and policy settings can materially affect yields, liquidity, and financial conditions.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures